Strides Pharma Science share news and announcements
NSE: STARBSE: 532531Pharmaceuticals & BiotechnologySmall Cap
Formerly Strides Shasun
Last close ₹1,014.80up ₹16.40 (1.64%)BSE ₹1,012.15
Share price at the NSE close on 23 Oct 2026. Previous close ₹998.40.
52-week range of traded prices to 23 Oct 2026
₹768.65Low, 29 Jan 2026₹1,260.90High, 21 Sep 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹9,354 Cr580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- 15.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- 3.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.49%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 21.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,12,38541.2% delivered
Strides Pharma Science share news and announcements
1,456 announcements, routine notices left out, newest first. Page 23 of 30.
Nov 2011
11 Nov · Issue of Securities
Board of Directors have approved issue of upto 6,200,000 warrants on a preferential basis to the Promoters / Promoter Group, subject to shareholders' approval and necessary regulatory approvals. The warrants will be convertible into equivalent number of equity shares of Rs.10/- each and will be issued at Rs. 425/- per warrant, which price is not lower than the price specified in Chapter VII of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 and on such further terms and conditions specified in the said guidelines.
Oct 2011
17 Oct · Business
Company has allotted 6,000 fully paid equity shares of Rs. 10/- each on conversion of employee stock options under Strides Arcolab ESOP 2008 Scheme. Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs. 583,741,710/- consisting of 58,374,171 equity shares of Rs. 10/- each to Rs. 583,801,710 consisting of 58,380,171 equity shares of Rs. 10/- each.14 Oct · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended September 30, 2011.
Sep 2011
29 Sep · Business
Company has allotted 38,250 fully paid equity shares of Rs. 10/- each on conversion of employee stock options under Strides Arcolab ESOP 2008 Scheme. Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs. 583,359,710/- consisting of 583,335,921 equity shares of Rs. 10/- each to Rs. 583,741,710 consisting of 58,374,171 equity shares of Rs. 10/- each.22 Sep · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Strides Arcolab Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Strides Arcolab Limited has vide its letter inter-alia stated,"There are no material events/price sensitive information/announcement (including pending announcement) which the Company has not disclosed to the exchange."16 Sep · Business
Company has allotted 29,250 fully paid equity shares of Rs. 10/- each on conversion of employee stock options under Strides Arcolab ESOP 2008 Scheme. Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs. 583,066,710/- consisting of 58,306,671 equity shares of Rs. 10/- each to Rs. 583,359,210 consisting of 58,335,921 equity shares of Rs. 10/- each.16 Sep · Meeting
Based on the Scrutinizer's Report dated September 13, 2011, the resolution seeking approval of the shareholders through Postal Ballot concerning revision of remuneration of Mr. V S Iyer, Executive Director of the Company has been passed with requisite majority.
Aug 2011
27 Aug · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended June 30,2011 A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Aug · Business
Company has allotted 132,500 fully paid equity shares of Rs. 10/- each on conversion of employee stock options under Strides Arcolab ESOP 2008 Scheme. Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs. 581,741,710 consisting of 58,174,171 equity shares of Rs. 10/- each to Rs. 583,066,710 consisting of 58,306,671 equity shares of Rs. 10/- each.18 Aug · Business
Company has allotted 82,500 fully paid equity shares of Rs. 10/- each on conversion of employee stock options under Strides Arcolab ESOP 2008 Scheme.Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs. 580,916,710.00 consisting of 58,091,671 equity shares of Rs. 10/- each to Rs. 581,741,710.00 consisting of 58,174,171 equity shares of Rs. 10/- each.
Jul 2011
29 Jul · Business
Company has allotted 67,500 fully paid equity shares of Rs. 10/- each on conversion of employee stock options under Strides Arcolab ESOP 2008 Scheme. Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs.580,241,710.00 consisting of 58,024,171 equity shares of Rs.10/- each to Rs.580,916,710.00 consisting of 58,091,671 equity shares of Rs. 10/- each.27 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 58125.46 lacs for quarter ending on 30-JUN-2011 against Rs. 45446.57 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 6889.08 lacs for the quarter ending on 30-JUN-2011 against Rs. 4575.65 lacs for the quarter ending on 30-JUN-2010.27 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 19768.71 lacs for quarter ending on 30-JUN-2011 against Rs. 11861.9 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 1460.78 lacs for the quarter ending on 30-JUN-2011 against Rs. (1358.82) lacs for the quarter ending on 30-JUN-2010.19 Jul · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended June 30, 2011.
Jun 2011
May 2011
26 May · Disclosure
Compensation Committee of the Company has granted 9,000 options to eligible employees under the Strides Arcolab ESOP 2008 Schemes at an exercise price Rs.312.15 per option. The shares covered by such options are 9,000 shares. The vesting period of these options is in a phased manner over a period of 3 years. The options may be exercised within a period of 30 days from the date of vesting.